References
Ahn S, Lee YS, Lim KS, Lee JL (2013) Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 21:2303–2308
Robinson JO, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O (2011) Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? Plos One 6
Svaldi M, Hirber J, Lanthaler AI, Mayr O, Faes S, Peer E, Mitterer M (2001) Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol 115:53–57
Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407
Conflict of interest
None to declare.
The author has full control of all primary data and agrees to allow the journal to review the data if requested.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahn, S. Author’s response to ‘procalcitonin in febrile neutropenia—timing is important’. Support Care Cancer 22, 585–586 (2014). https://doi.org/10.1007/s00520-013-2109-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-013-2109-8